Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Mizuho biotech analyst to hold an analyst/industry conference call » 09:50
05/24/23
05/24
09:50
05/24/23
09:50
ERAS

Erasca

$2.96 /

-0.03 (-1.00%)

, IMRX

Immuneering

$6.95 /

+ (+0.00%)

, VSTM

Verastem

/

+

, MRK

Merck

$112.88 /

-0.42 (-0.37%)

, INCY

Incyte

$64.67 /

-0.435 (-0.67%)

, EFTR

eFfector Therapeutics

/

+

, LPTX

Leap Therapeutics

/

+

, RCUS

Arcus Biosciences

$17.94 /

-0.14 (-0.77%)

, CRVS

Corvus Pharmaceuticals

$3.00 /

-0.09 (-2.91%)

Biotechnology Analyst…

Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am.

ShowHide Related Items >><<
VSTM Verastem
/

+

RCUS Arcus Biosciences
$17.94 /

-0.14 (-0.77%)

MRK Merck
$112.88 /

-0.42 (-0.37%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$64.67 /

-0.435 (-0.67%)

IMRX Immuneering
$6.95 /

+ (+0.00%)

ERAS Erasca
$2.96 /

-0.03 (-1.00%)

EFTR eFfector Therapeutics
/

+

CRVS Corvus Pharmaceuticals
$3.00 /

-0.09 (-2.91%)

ERAS Erasca
$2.96 /

-0.03 (-1.00%)

03/29/23 Mizuho
Erasca initiated with a Buy at Mizuho
02/24/23 Goldman Sachs
Erasca initiated with a Buy at Goldman Sachs
02/03/23 Morgan Stanley
Erasca upgraded to Overweight from Equal Weight at Morgan Stanley
IMRX Immuneering
$6.95 /

+ (+0.00%)

04/19/23 Mizuho
Immuneering upgraded to Buy from Neutral at Mizuho
04/19/23 Morgan Stanley
Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley
04/18/23 Chardan
Immuneering price target raised to $22 from $18 at Chardan
03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
VSTM Verastem
/

+

05/10/23 H.C. Wainwright
Verastem price target lowered to $2 from $3 at H.C. Wainwright
03/29/23 Mizuho
Verastem initiated with a Neutral at Mizuho
11/07/22 H.C. Wainwright
Verastem price target lowered to $3 from $5 at H.C. Wainwright
10/05/22 BTIG
Verastem price target lowered to $5 from $8 at BTIG
MRK Merck
$112.88 /

-0.42 (-0.37%)

05/10/23 Jefferies
Prometheus downgraded to Hold from Buy at Jefferies
05/01/23 Barclays
Merck price target raised to $130 from $128 at Barclays
04/18/23 Wells Fargo
Prometheus downgraded to Equal Weight from Overweight at Wells Fargo
04/18/23 RBC Capital
Prometheus downgraded to Sector Perform from Outperform at RBC Capital
INCY Incyte
$64.67 /

-0.435 (-0.67%)

05/04/23 JMP Securities
Incyte price target lowered to $93 from $113 at JMP Securities
05/04/23 BofA
Incyte downgraded to Neutral at BofA on long-term value uncertainty
05/04/23 BofA
Incyte downgraded to Neutral from Buy at BofA
05/03/23 BMO Capital
Incyte price target lowered to $70 from $75 at BMO Capital
EFTR eFfector Therapeutics
/

+

LPTX Leap Therapeutics
/

+

03/17/23 Piper Sandler
Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler
03/17/23 Mizuho
Leap Therapeutics price target lowered to $2 from $3 at Mizuho
01/27/23 Mizuho
Leap Therapeutics price target lowered to $3 from $6 at Mizuho
01/17/23 Piper Sandler
Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler
RCUS Arcus Biosciences
$17.94 /

-0.14 (-0.77%)

03/09/23 Citi
Arcus Biosciences price target lowered to $40 from $42 at Citi
12/21/22 Citi
Arcus Biosciences selloff a buying opportunity, says Citi
12/21/22 Barclays
Arcus Biosciences price target lowered to $36 from $60 at Barclays
12/20/22 Citi
Arcus Biosciences price target raised to $42 from $37 at Citi
CRVS Corvus Pharmaceuticals
$3.00 /

-0.09 (-2.91%)

05/09/23 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald
10/07/22 Ladenburg
Corvus Pharmaceuticals initiated with a Buy at Ladenburg
08/09/22 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald
VSTM Verastem
/

+

RCUS Arcus Biosciences
$17.94 /

-0.14 (-0.77%)

MRK Merck
$112.88 /

-0.42 (-0.37%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$64.67 /

-0.435 (-0.67%)

ERAS Erasca
$2.96 /

-0.03 (-1.00%)

EFTR eFfector Therapeutics
/

+

CRVS Corvus Pharmaceuticals
$3.00 /

-0.09 (-2.91%)

  • 18
    Apr
  • 09
    Dec
MRK Merck
$112.88 /

-0.42 (-0.37%)

VSTM Verastem
/

+

RCUS Arcus Biosciences
$17.94 /

-0.14 (-0.77%)

MRK Merck
$112.88 /

-0.42 (-0.37%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$64.67 /

-0.435 (-0.67%)

ERAS Erasca
$2.96 /

-0.03 (-1.00%)

MRK Merck
$112.88 /

-0.42 (-0.37%)

Conference/Events
Mizuho biotech analyst to hold an analyst/industry conference call » 04:55
05/24/23
05/24
04:55
05/24/23
04:55
ERAS

Erasca

$3.00 /

+0.075 (+2.57%)

, IMRX

Immuneering

$6.95 /

-1.23 (-15.04%)

, VSTM

Verastem

/

+

, MRK

Merck

$113.28 /

-1.175 (-1.03%)

, INCY

Incyte

$65.11 /

+0.715 (+1.11%)

, EFTR

eFfector Therapeutics

/

+

, LPTX

Leap Therapeutics

/

+

, RCUS

Arcus Biosciences

$18.06 /

-0.08 (-0.44%)

, CRVS

Corvus Pharmaceuticals

$3.09 /

-0.28 (-8.31%)

Biotechnology Analyst…

Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am.

ShowHide Related Items >><<
VSTM Verastem
/

+

RCUS Arcus Biosciences
$18.06 /

-0.08 (-0.44%)

MRK Merck
$113.28 /

-1.175 (-1.03%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$65.11 /

+0.715 (+1.11%)

IMRX Immuneering
$6.95 /

-1.23 (-15.04%)

ERAS Erasca
$3.00 /

+0.075 (+2.57%)

EFTR eFfector Therapeutics
/

+

CRVS Corvus Pharmaceuticals
$3.09 /

-0.28 (-8.31%)

ERAS Erasca
$3.00 /

+0.075 (+2.57%)

03/29/23 Mizuho
Erasca initiated with a Buy at Mizuho
02/24/23 Goldman Sachs
Erasca initiated with a Buy at Goldman Sachs
02/03/23 Morgan Stanley
Erasca upgraded to Overweight from Equal Weight at Morgan Stanley
IMRX Immuneering
$6.95 /

-1.23 (-15.04%)

04/19/23 Mizuho
Immuneering upgraded to Buy from Neutral at Mizuho
04/19/23 Morgan Stanley
Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley
04/18/23 Chardan
Immuneering price target raised to $22 from $18 at Chardan
03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
VSTM Verastem
/

+

05/10/23 H.C. Wainwright
Verastem price target lowered to $2 from $3 at H.C. Wainwright
03/29/23 Mizuho
Verastem initiated with a Neutral at Mizuho
11/07/22 H.C. Wainwright
Verastem price target lowered to $3 from $5 at H.C. Wainwright
10/05/22 BTIG
Verastem price target lowered to $5 from $8 at BTIG
MRK Merck
$113.28 /

-1.175 (-1.03%)

05/10/23 Jefferies
Prometheus downgraded to Hold from Buy at Jefferies
05/01/23 Barclays
Merck price target raised to $130 from $128 at Barclays
04/18/23 Wells Fargo
Prometheus downgraded to Equal Weight from Overweight at Wells Fargo
04/18/23 RBC Capital
Prometheus downgraded to Sector Perform from Outperform at RBC Capital
INCY Incyte
$65.11 /

+0.715 (+1.11%)

05/04/23 JMP Securities
Incyte price target lowered to $93 from $113 at JMP Securities
05/04/23 BofA
Incyte downgraded to Neutral at BofA on long-term value uncertainty
05/04/23 BofA
Incyte downgraded to Neutral from Buy at BofA
05/03/23 BMO Capital
Incyte price target lowered to $70 from $75 at BMO Capital
EFTR eFfector Therapeutics
/

+

LPTX Leap Therapeutics
/

+

03/17/23 Piper Sandler
Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler
03/17/23 Mizuho
Leap Therapeutics price target lowered to $2 from $3 at Mizuho
01/27/23 Mizuho
Leap Therapeutics price target lowered to $3 from $6 at Mizuho
01/17/23 Piper Sandler
Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler
RCUS Arcus Biosciences
$18.06 /

-0.08 (-0.44%)

03/09/23 Citi
Arcus Biosciences price target lowered to $40 from $42 at Citi
12/21/22 Citi
Arcus Biosciences selloff a buying opportunity, says Citi
12/21/22 Barclays
Arcus Biosciences price target lowered to $36 from $60 at Barclays
12/20/22 Citi
Arcus Biosciences price target raised to $42 from $37 at Citi
CRVS Corvus Pharmaceuticals
$3.09 /

-0.28 (-8.31%)

05/09/23 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald
10/07/22 Ladenburg
Corvus Pharmaceuticals initiated with a Buy at Ladenburg
08/09/22 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald
VSTM Verastem
/

+

RCUS Arcus Biosciences
$18.06 /

-0.08 (-0.44%)

MRK Merck
$113.28 /

-1.175 (-1.03%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$65.11 /

+0.715 (+1.11%)

ERAS Erasca
$3.00 /

+0.075 (+2.57%)

EFTR eFfector Therapeutics
/

+

CRVS Corvus Pharmaceuticals
$3.09 /

-0.28 (-8.31%)

  • 18
    Apr
  • 09
    Dec
MRK Merck
$113.28 /

-1.175 (-1.03%)

VSTM Verastem
/

+

RCUS Arcus Biosciences
$18.06 /

-0.08 (-0.44%)

MRK Merck
$113.28 /

-1.175 (-1.03%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$65.11 /

+0.715 (+1.11%)

ERAS Erasca
$3.00 /

+0.075 (+2.57%)

MRK Merck
$113.28 /

-1.175 (-1.03%)

Over a week ago
Conference/Events
Mizuho biotech analyst to hold an analyst/industry conference call » 16:33
05/18/23
05/18
16:33
05/18/23
16:33
ERAS

Erasca

$2.76 /

-0.14 (-4.84%)

, IMRX

Immuneering

$8.90 /

+0.25 (+2.89%)

, VSTM

Verastem

/

+

, MRK

Merck

$114.03 /

-0.75 (-0.65%)

, INCY

Incyte

$63.61 /

-0.92 (-1.43%)

, EFTR

eFfector Therapeutics

/

+

, LPTX

Leap Therapeutics

/

+

, RCUS

Arcus Biosciences

$17.63 /

-0.51 (-2.81%)

, CRVS

Corvus Pharmaceuticals

$3.25 /

+0.01 (+0.31%)

Biotechnology Analyst…

Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am.

ShowHide Related Items >><<
VSTM Verastem
/

+

RCUS Arcus Biosciences
$17.63 /

-0.51 (-2.81%)

MRK Merck
$114.03 /

-0.75 (-0.65%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$63.61 /

-0.92 (-1.43%)

IMRX Immuneering
$8.90 /

+0.25 (+2.89%)

ERAS Erasca
$2.76 /

-0.14 (-4.84%)

EFTR eFfector Therapeutics
/

+

CRVS Corvus Pharmaceuticals
$3.25 /

+0.01 (+0.31%)

ERAS Erasca
$2.76 /

-0.14 (-4.84%)

03/29/23 Mizuho
Erasca initiated with a Buy at Mizuho
02/24/23 Goldman Sachs
Erasca initiated with a Buy at Goldman Sachs
02/03/23 Morgan Stanley
Erasca upgraded to Overweight from Equal Weight at Morgan Stanley
IMRX Immuneering
$8.90 /

+0.25 (+2.89%)

04/19/23 Mizuho
Immuneering upgraded to Buy from Neutral at Mizuho
04/19/23 Morgan Stanley
Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley
04/18/23 Chardan
Immuneering price target raised to $22 from $18 at Chardan
03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
VSTM Verastem
/

+

05/10/23 H.C. Wainwright
Verastem price target lowered to $2 from $3 at H.C. Wainwright
03/29/23 Mizuho
Verastem initiated with a Neutral at Mizuho
11/07/22 H.C. Wainwright
Verastem price target lowered to $3 from $5 at H.C. Wainwright
10/05/22 BTIG
Verastem price target lowered to $5 from $8 at BTIG
MRK Merck
$114.03 /

-0.75 (-0.65%)

05/10/23 Jefferies
Prometheus downgraded to Hold from Buy at Jefferies
05/01/23 Barclays
Merck price target raised to $130 from $128 at Barclays
04/18/23 Wells Fargo
Prometheus downgraded to Equal Weight from Overweight at Wells Fargo
04/18/23 RBC Capital
Prometheus downgraded to Sector Perform from Outperform at RBC Capital
INCY Incyte
$63.61 /

-0.92 (-1.43%)

05/04/23 JMP Securities
Incyte price target lowered to $93 from $113 at JMP Securities
05/04/23 BofA
Incyte downgraded to Neutral at BofA on long-term value uncertainty
05/04/23 BofA
Incyte downgraded to Neutral from Buy at BofA
05/03/23 BMO Capital
Incyte price target lowered to $70 from $75 at BMO Capital
EFTR eFfector Therapeutics
/

+

LPTX Leap Therapeutics
/

+

03/17/23 Piper Sandler
Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler
03/17/23 Mizuho
Leap Therapeutics price target lowered to $2 from $3 at Mizuho
01/27/23 Mizuho
Leap Therapeutics price target lowered to $3 from $6 at Mizuho
01/17/23 Piper Sandler
Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler
RCUS Arcus Biosciences
$17.63 /

-0.51 (-2.81%)

03/09/23 Citi
Arcus Biosciences price target lowered to $40 from $42 at Citi
12/21/22 Citi
Arcus Biosciences selloff a buying opportunity, says Citi
12/21/22 Barclays
Arcus Biosciences price target lowered to $36 from $60 at Barclays
12/20/22 Citi
Arcus Biosciences price target raised to $42 from $37 at Citi
CRVS Corvus Pharmaceuticals
$3.25 /

+0.01 (+0.31%)

05/09/23 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald
10/07/22 Ladenburg
Corvus Pharmaceuticals initiated with a Buy at Ladenburg
08/09/22 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald
VSTM Verastem
/

+

RCUS Arcus Biosciences
$17.63 /

-0.51 (-2.81%)

MRK Merck
$114.03 /

-0.75 (-0.65%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$63.61 /

-0.92 (-1.43%)

ERAS Erasca
$2.76 /

-0.14 (-4.84%)

EFTR eFfector Therapeutics
/

+

CRVS Corvus Pharmaceuticals
$3.25 /

+0.01 (+0.31%)

  • 18
    Apr
  • 09
    Dec
MRK Merck
$114.03 /

-0.75 (-0.65%)

VSTM Verastem
/

+

RCUS Arcus Biosciences
$17.63 /

-0.51 (-2.81%)

MRK Merck
$114.03 /

-0.75 (-0.65%)

LPTX Leap Therapeutics
/

+

INCY Incyte
$63.61 /

-0.92 (-1.43%)

ERAS Erasca
$2.76 /

-0.14 (-4.84%)

MRK Merck
$114.03 /

-0.75 (-0.65%)

Over a month ago
Upgrade
Immuneering upgraded to Buy from Neutral at Mizuho » 05:07
04/19/23
04/19
05:07
04/19/23
05:07
IMRX

Immuneering

$13.37 /

+0.85 (+6.79%)

Mizuho analyst Mara…

Mizuho analyst Mara Goldstein upgraded Immuneering to Buy from Neutral with a price target of $20, up from $10, following a presentation of IMM-1-104 data. The data presented shows IMM-1-104's PK profile is consistent with what was predicted preclinically, which provides "initial validation," the analyst tells investors in a research note. The data, from an initial four patients, showed a profile consistent with preclinical work with a tolerable safety profile thus far, says the firm, As a result, it increased its probability of success for IMM-1-104.

ShowHide Related Items >><<
IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

04/19/23 Morgan Stanley
Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley
04/18/23 Chardan
Immuneering price target raised to $22 from $18 at Chardan
03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
02/03/23 Morgan Stanley
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

  • 18
    Apr
Upgrade
Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley » 04:49
04/19/23
04/19
04:49
04/19/23
04:49
IMRX

Immuneering

$13.37 /

+0.85 (+6.79%)

Morgan Stanley upgraded…

Morgan Stanley upgraded Immuneering to Equal Weight from Underweight with a price target of $14, up from $5. The company accelerated timelines for its Phase 1 study with a recommended Phase 2 dose expected by early 2024, the analyst tells investors in a research note. The firm cites "encouraging" initial results and greater clarity on the timing of upcoming catalysts for the upgrade.

ShowHide Related Items >><<
IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

04/18/23 Chardan
Immuneering price target raised to $22 from $18 at Chardan
03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
02/03/23 Morgan Stanley
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

  • 18
    Apr
Recommendations
Immuneering price target raised to $22 from $18 at Chardan » 16:40
04/18/23
04/18
16:40
04/18/23
16:40
IMRX

Immuneering

$13.37 /

+0.85 (+6.79%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits raised the firm's price target on Immuneering to $22 from $18 and keeps a Buy rating on the shares. The company presented initial human data from the Phase I/IIa trial of lead MEK inhibitor IMM-1-104 demonstrating a two hour half-life consistent with preclinical modeling and transient~90% MAPK pathway suppression as measured by pERK, the analyst tells investors in a research note. The analyst says the data support translatability for IMM-1-104.

ShowHide Related Items >><<
IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
02/03/23 Morgan Stanley
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
09/30/22 Piper Sandler
Immuneering transitions to clinical stage with IND approval, says Piper Sandler
IMRX Immuneering
$13.37 /

+0.85 (+6.79%)

Hot Stocks
Immuneering down 5% at $11.53 after pricing $30M stock offering  09:27
04/18/23
04/18
09:27
04/18/23
09:27
IMRX

Immuneering

$12.42 /

+0.02 (+0.16%)

 
ShowHide Related Items >><<
IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
02/03/23 Morgan Stanley
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
09/30/22 Piper Sandler
Immuneering transitions to clinical stage with IND approval, says Piper Sandler
IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

Syndicate
Immuneering prices 2.73M share underwritten offering at $11 per share » 09:25
04/18/23
04/18
09:25
04/18/23
09:25
IMRX

Immuneering

$12.42 /

+0.02 (+0.16%)

Immuneering…

Immuneering "announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share. The gross proceeds from the offering are expected be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering. Jefferies, TD Cowen and Guggenheim Securities are acting as the joint book-running managers for the offering."

ShowHide Related Items >><<
IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
02/03/23 Morgan Stanley
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
09/30/22 Piper Sandler
Immuneering transitions to clinical stage with IND approval, says Piper Sandler
IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

Hot Stocks
Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 » 09:06
04/18/23
04/18
09:06
04/18/23
09:06
IMRX

Immuneering

$12.42 /

+0.02 (+0.16%)

Immuneering announced…

Immuneering announced positive initial pharmacokinetic, PK, pharmacodynamic, PD, and safety data from the Phase 1 trial of IMM-1-104, which are being shared today in a poster presentation titled "Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors" at the American Association for Cancer Research, AACR, annual meeting. "We are very pleased to share initial PK, PD and safety data from our Phase 1 trial of IMM-1-104 in patients with advanced RAS mutant solid tumors, ahead of schedule," said Ben Zeskind, Ph.D., MBA, Co-founder, and Chief Executive Officer of Immuneering. "We believe these data from the first patients dosed in our study demonstrate the PK, PD and safety profile necessary for deep cyclic inhibition - the proprietary and novel mechanism through which our therapies are designed to selectively impact cancer cells to a greater extent than healthy cells, regardless of the specific RAS mutation driving the tumor. The data show that we were able to reach significant levels of PK Cmax with the aim of breaking tumor addiction to the MAPK pathway, then rapidly clearing out drug with IMM-1-104's short half-life. These results position us to accelerate the dose escalation portion of our study, reaching potentially therapeutic levels of IMM-1-104 earlier than previously planned." The Phase 1/2a clinical trial is an open-label study designed to evaluate the safety, tolerability, PK and preliminary efficacy of IMM-1-104 in patients with advanced RAS mutant solid tumors. The Phase 1 portion of the study, which is being conducted at five clinical sites in the United States, is evaluating IMM-1-104 following a Bayesian mTPI-2 escalation design, which includes a dose escalation phase and dose evaluation phase to establish an optimized RP2D candidate. Following selection of the RP2D candidate, the Company expects to conduct a Phase 2a dose expansion phase to assess the safety and efficacy of IMM-1-104 at the RP2D in RAS mutated pancreatic, melanoma, lung and colorectal cancers.

ShowHide Related Items >><<
IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

03/29/23 Mizuho
Immuneering initiated with a Neutral at Mizuho
02/03/23 Morgan Stanley
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
09/30/22 Piper Sandler
Immuneering transitions to clinical stage with IND approval, says Piper Sandler
IMRX Immuneering
$12.42 /

+0.02 (+0.16%)

Initiation
Immuneering initiated with a Neutral at Mizuho » 16:21
03/29/23
03/29
16:21
03/29/23
16:21
IMRX

Immuneering

$9.72 /

+0.19 (+1.99%)

Mizuho analyst Mara…

Mizuho analyst Mara Goldstein initiated coverage of Immuneering with a Neutral rating and $10 price target. The shares have doubled year-to-date following news that interim Phase I dose escalation IMM-1-104 data will be available in Q2, but clinical evidence of feasibility is now needed to expand the valuation further, the analyst tells investors in a research note.

ShowHide Related Items >><<
IMRX Immuneering
$9.72 /

+0.19 (+1.99%)

IMRX Immuneering
$9.72 /

+0.19 (+1.99%)

02/03/23 Morgan Stanley
Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
09/30/22 Piper Sandler
Immuneering transitions to clinical stage with IND approval, says Piper Sandler
07/25/22 Piper Sandler
Immuneering CFO departure not a 'red flag,' says Piper Sandler
IMRX Immuneering
$9.72 /

+0.19 (+1.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.